SPAC Ash­ing­ton In­no­va­tion plans to ac­quire dor­mant biotech Celixir and lead heart fail­ure pro­gram for $172M

Lon­don-based SPAC Ash­ing­ton In­no­va­tion is plan­ning to ac­quire dor­mant, UK-based biotech Celixir for $172 mil­lion (£135 mil­lion) in an all-share trans­ac­tion, tak­ing over its lead pro­gram for a heart fail­ure drug.

In or­der to pay for Celixir, Ash­ing­ton said it will place new or­di­nary shares to raise up to £3 mil­lion to fi­nance drug de­vel­op­ment and work­ing cap­i­tal.

Ja­son Smart, the founder of Ash­ing­ton In­no­va­tion, said in a state­ment that “the pro­posed ac­qui­si­tion meets our stat­ed ob­jec­tive of iden­ti­fy­ing a po­ten­tial­ly ex­treme­ly valu­able en­ti­ty ca­pa­ble of sus­tain­able de­vel­op­ment and with sig­nif­i­cant tech­no­log­i­cal ad­van­tages.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER